De Tijd and L'Echo report the decision, which follows the same call Vandenbroucke made earlier on Wegovy.
Recap by typeshit. Post by @belga_english on Instagram.
The new Medicare program could cut GLP-1 costs by thousands for people on it, though many beneficiaries will not meet the eligibility rules.
KTSM breaks down which Medicare enrollees are eligible for GLP-1 drugs at a $50 monthly cost.
Men's Journal looks at the extra spending that comes with GLP-1 drugs beyond the prescription price, as these meds reshape weight loss.
The Times reports plans that could put Wegovy on Ireland's public health service, a potential shift in who can get the drug without paying privately.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Stanford researchers found that blocking a protein could point toward a shot or pill that regrows cartilage, an idea Forbes compares to GLP-1 drugs.
Loading…